Julia T. Warren, MD, PhD, discusses the goals and eligibility criteria of the phase 3 4WARD trial of mavorixafor in chronic neutropenia.
Julia T. Warren, MD, PhD
Advertisement
Articles by Julia T. Warren, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
Five Under 5: Top Oncology Videos for the Week of 10/12
4
Early-Phase INCA33890 Data Lay the Foundation for Phase 3 Combination Research in MSS CRC
5